Evidence map›Paper›PMID 36328741›Full record

ArticleJournal of advanced research2022

3D-MSCs A151 ODN-loaded exosomes are immunomodulatory and reveal a proteomic cargo that sustains wound resolution.

Sérgio P Camões, Ozlem Bulut, Volkan Yazar, Maria M Gaspar, Sandra Simões, Rita Ferreira, Rui Vitorino, Jorge M Santos, Ihsan Gursel, Joana P Miranda

Open access · goldAbstract read
In one paragraph

Article in Journal of advanced research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Sérgio P CamõesResearch Institute for Medicines (imed), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Ozlem BulutMolecular Biology and Genetics Department, Thorlab, Bilkent University, Ankara, Turkey.
Volkan YazarInstitute for Cell Engineering, Johns Hopkins Medical Institute, Baltimore, MD, USA.
Maria M GasparResearch Institute for Medicines (imed), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Sandra SimõesResearch Institute for Medicines (imed), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal.
Rita FerreiraQOPNA, Mass Spectrometry Center, Department of Chemistry, University of Aveiro, Aveiro, Portugal.
Rui VitorinoDepartment of Surgery and Physiology, Cardiovascular R&D Center, Faculty of Medicine of the University of Porto, Oporto, Portugal; Department of Medical Sciences, Institute of Biomedicine (iBiMED), University of Aveiro, Aveiro, Portugal.
Jorge M SantosITQB, Universidade Nova de Lisboa, Oeiras, Portugal.
Ihsan GurselMolecular Biology and Genetics Department, Thorlab, Bilkent University, Ankara, Turkey.
Joana P MirandaResearch Institute for Medicines (imed), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal. Electronic address: jmiranda@ff.ulisboa.pt.
University of Lisbon · PTBilkent University · TRUniversidade do Porto · PTUniversidade Nova de Lisboa · PTUniversity of Aveiro · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNon-healing wounds remain a major burden due to the lack of effective treatments. Mesenchymal stem cell-derived exosomes (MSC-Exo) have emerged as therapeutic options given their pro-regenerative and immunomodulatory features. Still, little is known on the exact mechanisms mediated by MSC-Exo. Importantly, modulation of their efficacy through 3D-physiologic cultures together with loading strategies continues underexplored.

objectivesTo uncover the MSC-Exo-mediated mechanism via proteomic analyses, and to use 3D-culture and loading technologies to expand MSC-Exo efficacy for cutaneous wound healing.

methodsMSC-Exo were produced in either 3D or 2D cultures (Exo3D/Exo2D) and loaded with an exogenous immunosuppressive oligodeoxynucleotide (A151 ODN). Both, loaded and naïve exosomes were characterised regarding size, morphology and the presence of specific protein markers; while IPA analyses enabled to correlate their protein content with the effects observed in vitro and in vivo. The Exo3D/Exo2D regenerative potential was evaluated in vitro by assessing keratinocyte and fibroblast mitogenicity, motogenicity, and cytokine secretion as well as using an in vivo wound splinting model. Accordingly, the modulation of inflammatory and immune responses by A151-loaded Exo3D/Exo2D was also assessed.

resultsExo3D stimulated mitogenically and motogenically keratinocytes and fibroblasts in vitro, with upregulation of IL-1α and VEGF-α or increased secretion of TGF-β, TNF-α and IL-10. In vivo, Exo3D reduced the granulation tissue area and promoted complete re-epithelization of the wound. These observations were sustained by the proteomic profiling of the Exo3D cargo that identified wound healing-related proteins, such as TGF-β, ITGA1-3/5, IL-6, CDC151, S100A10 and Wnt5α. Moreover, when loaded with A151 ODN, Exo3D differentially mediated wound healing-related trophic factors reducing the systemic levels of IL-6 and TNF-α at the late stage of wound healing in vivo.

conclusionOur results support the potential of A151-loaded Exo3D for the treatment of chronic wounds by promoting skin regeneration, while modulating the systemic levels of the pro-inflammatory cytokines.

Indexed as

ExosomesImmunityInterleukin-6ProteomicsTransforming Growth Factor betaTumor Necrosis Factor-alphaInterleukin-6Transforming Growth Factor betaTumor Necrosis Factor-alpha3D-cultured mesenchymal stem/stromal cellsExosomesImmunomodulationImmunosuppressive oligodeoxynucleotide loadingProteomicsWound healing

Identifiers

PMID36328741
PMCPMC9637564
OpenAlexW4210628040

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.